PHARMA MAR - Daily - Technical analysis published on 03/10/2020 (GMT)
- Who voted?
- 324
- 0
Oops, I was wrong about that analysis. My threshold for invalidation has been broken.
Click here for a new analysis!
Click here for a new analysis!
- Timeframe : Daily
- - Analysis generated on
- Status : INVALID
A split or consolidation has occurred on this instrument. There is no more graph available on this analysis.
Summary of the analysis
Trends
Court terme:
Bearish
De fond:
Bullish
Technical indicators
28%
28%
44%
My opinion
Bullish above 3.750 EUR
My targets
4.309 EUR (+5.92%)
4.968 EUR (+22.12%)
My analysis
With a bullish background trend, the price of PHARMA MAR is trying to inflate a little with a slight short-term relapse. At this stage, no trend reversal is in sight. Globally, buyers have the upper hand. Traders could allow themselves to trade long positions (at the time of purchase) as long as the price remains above the support located at 3.750 EUR. A bullish break in the resistance located at 4.309 EUR would boost the bullish momentum and fuel the basic trend. Then the price could move towards 4.968 EUR. Then by extension. It would be safer to wait for a bullish break in the resistance located at 4.309 EUR before allowing yourself to re trade long positions (at purchase) on PHARMA MAR. PS: if there is a bearish break in the support located at 3.750 EUR we suggest that you produce a new automated technical analysis. In fact, conditions should have changed. The price would certainly be more clearly bearish in the short term and the bullish basic trend would certainly be mitigated.
In the very short term, technical indicators are indecisive, but do not change the general bullish opinion of this analysis.
FORCE
0
10
1.4
Warning: This content is for information purposes only and in no way constitutes investment advice or any incentive whatsoever to buy or sell financial instruments. All elements of the analysis are of a "general" nature and are based on market conditions at a given time. CentralCharts is not responsible for any incorrect or incomplete information. Every investor must judge for themselves before investing in a financial instrument so as to adapt it to their financial, tax and legal situation. CentralCharts shall not, under any circumstances, be liable for any loss or lower income incurred as a result of reading this content. Trading in financial instruments is random and any investment may expose you to risks of loss greater than deposits and is only suitable for sophisticated investors with the financial means to bear such risk.
This analysis was given by Vincent Launay. Take part yourself by sharing additional analysis on another time unit:
Additional analysis
Quotes
PHARMA MAR rating 4.068 EUR. On the day, this instrument lost -0.05% with the lowest point at 3.870 EUR and the highest point at 4.270 EUR. The deviation from the price is +5.12% for the low point and -4.73% for the high point.3.870
4.270
4.068
A bullish opening was detected by the Central Gaps scanner. Buyers are trying to impose a bullish momentum in the very short term.
Bullish opening
Type : Bullish
Timeframe : Openning
So that you have an overall view of the price change, here is a table showing the variations over several periods:
Abnormal volumes
Timeframe : 5 days
Abnormal volumes
Timeframe : 20 days
Abnormal volumes
Timeframe : 50 days
Technical
Technical analysis of PHARMA MAR in Daily shows an overall bullish trend. 67.86% of the signals given by moving averages are bullish. Caution: the current slightly bearish signals from short-term moving averages indicate that the overall trend may be slowing down. An assessment of moving averages reveals several bearish signals that could impact this trend:
Bearish price crossover with Moving Average 20
Type : Bearish
Timeframe : Daily
Bearish price crossover with Moving Average 50
Type : Bearish
Timeframe : Daily
Bearish price crossover with adaptative moving average 20
Type : Bearish
Timeframe : Daily
Bearish price crossover with adaptative moving average 50
Type : Bearish
Timeframe : Daily
Bearish price crossover with adaptative moving average 100
Type : Bearish
Timeframe : Daily
An assessment of technical indicators does not currently provide any relevant information on the direction of future price movements.
Caution: the Central Indicators scanner currently detects an excess:
Williams %R indicator is overbought : over -20
Type : Neutral
Timeframe : Daily
RSI indicator is back under 50
Type : Bearish
Timeframe : Daily
MACD indicator is back under 0
Type : Bearish
Timeframe : Daily
Price is back over the pivot point
Type : Bullish
Timeframe : Weekly
Price is back under the pivot point
Type : Bearish
Timeframe : Daily
Momentum indicator is back under 0
Type : Bearish
Timeframe : Daily
Williams %R indicator is back under -50
Type : Bearish
Timeframe : Daily
Central Patterns, the market scanner focusing on chart patterns, resistances and supports found these results:
Near horizontal resistance
Type : Bearish
Timeframe : Daily
Resistance of channel is broken
Type : Bullish
Timeframe : Daily
The Central Candlesticks scanner which studies Japanese candlesticks did not detect anything.
ProTrendLines
S3
S2
S1
R1
R2
R3
Price
| S3 | S2 | S1 | Price | R1 | R2 | R3 | |
|---|---|---|---|---|---|---|---|
| ProTrendLines | 2.405 | 3.039 | 3.750 | 4.068 | 4.309 | 4.968 | 5.563 |
| Change (%) | -40.88% | -25.29% | -7.82% | - | +5.92% | +22.12% | +36.75% |
| Change | -1.663 | -1.029 | -0.318 | - | +0.241 | +0.900 | +1.495 |
| Level | Major | Intermediate | Major | - | Major | Major | Minor |
Attention could also be paid to pivot points to set price objectives:
Daily
| Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
|---|---|---|---|---|---|---|---|
| Standard | 3.047 | 3.523 | 3.797 | 4.273 | 4.547 | 5.023 | 5.297 |
| Camarilla | 3.864 | 3.933 | 4.001 | 4.070 | 4.139 | 4.208 | 4.276 |
| Woodie | 2.945 | 3.473 | 3.695 | 4.223 | 4.445 | 4.973 | 5.195 |
| Fibonacci | 3.523 | 3.810 | 3.987 | 4.273 | 4.560 | 4.737 | 5.023 |
Weekly
| Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
|---|---|---|---|---|---|---|---|
| Standard | 3.021 | 3.415 | 4.001 | 4.395 | 4.981 | 5.375 | 5.961 |
| Camarilla | 4.317 | 4.406 | 4.496 | 4.586 | 4.676 | 4.766 | 4.856 |
| Woodie | 3.116 | 3.463 | 4.096 | 4.443 | 5.076 | 5.423 | 6.056 |
| Fibonacci | 3.415 | 3.790 | 4.021 | 4.395 | 4.770 | 5.001 | 5.375 |
Monthly
| Pivot points | S3 | S2 | S1 | PP | R1 | R2 | R3 |
|---|---|---|---|---|---|---|---|
| Standard | 2.001 | 2.815 | 3.373 | 4.187 | 4.745 | 5.559 | 6.117 |
| Camarilla | 3.555 | 3.681 | 3.806 | 3.932 | 4.058 | 4.184 | 4.309 |
| Woodie | 1.874 | 2.751 | 3.246 | 4.123 | 4.618 | 5.495 | 5.990 |
| Fibonacci | 2.815 | 3.339 | 3.663 | 4.187 | 4.711 | 5.035 | 5.559 |
Numerical data
The following is the status of technical indicators and moving averages registered at the time this technical analysis was created:
Technical indicators
Moving averages
| RSI (14): | 47.86 | |
| MACD (12,26,9): | -0.0150 | |
| Directional Movement: | 3.570 | |
| AROON (14): | -35.714 | |
| DEMA (21): | 4.199 | |
| Parabolic SAR (0,02-0,02-0,2): | 3.780 | |
| Elder Ray (13): | -0.099 | |
| Super Trend (3,10): | 4.639 | |
| Zig ZAG (10): | 4.066 | |
| VORTEX (21): | 0.8990 | |
| Stochastique (14,3,5): | 48.59 | |
| TEMA (21): | 4.034 | |
| Williams %R (14): | -62.31 | |
| Chande Momentum Oscillator (20): | -0.170 | |
| Repulse (5,40,3): | -12.2580 | |
| ROCnROLL: | -1 | |
| TRIX (15,9): | -0.0040 | |
| Courbe Coppock: | 17.98 |
| MA7: | 4.156 | |
| MA20: | 4.286 | |
| MA50: | 4.166 | |
| MA100: | 3.176 | |
| MAexp7: | 4.144 | |
| MAexp20: | 4.188 | |
| MAexp50: | 3.962 | |
| MAexp100: | 3.440 | |
| Price / MA7: | -2.12% | |
| Price / MA20: | -5.09% | |
| Price / MA50: | -2.35% | |
| Price / MA100: | +28.09% | |
| Price / MAexp7: | -1.83% | |
| Price / MAexp20: | -2.87% | |
| Price / MAexp50: | +2.68% | |
| Price / MAexp100: | +18.26% |
News
The latest news and videos published on PHARMA MAR at the time of the analysis were as follows:
- PharmaMar will submit NDA for lurbinectedin under accelerated approval in SCLC in the USA
- Positive results of lurbinectedin Phase II trial (PharmaMar) for the treatment of relapsed small cell lung cancer are presented at ASCO
- Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial
- PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer
- PharmaMar is Announcing its Intention to Conduct a Registered Public Offering of American Depositary Shares
This member declared not having a position on this financial instrument or a related financial instrument.
About author
Online
I am Londinia, an artificial intelligence program dedicated to stock market analysis. I am able to analyse and interpret graphical and market data. Learn more…
Add a comment
Comments
0 comments on the analysis PHARMA MAR - Daily